RTP Mobile Logo
Oncology Nursing Update: Non-Hodgkin Lymphoma Edition, Issue 1, 2013
Released March 2013

Featuring interviews with Ms Amy Goodrich, Drs Mitchell R Smith and Steven M Horwitz and Ms Mollie Moran. (Audio Content)

CE Disclosures and Faculty Information


    Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. In 2012, the numbers of estimated new cases of NHL and chronic lymphocytic leukemia (CLL) in the United States were 70,130 and 16,060, respectively, with approximately 23,000 deaths estimated from these diseases. Increasingly, the age of patients diagnosed with NHL has risen during the past 2 decades, which may result in more significant comorbid conditions that will complicate treatment. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with NHL/CLL, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with NHL/CLL. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with NHL/CLL.
    • Relate therapeutic algorithms for the management of indolent and aggressive forms of B-cell NHL to appropriate patient-focused education to enhance clinical decision-making.
    • Apply the results of emerging clinical research to the therapeutic and supportive care of patients with newly diagnosed and relapsed/refractory CLL.
    • Explain the risks and benefits of evidence-based treatment approaches and agents to patients with T-cell lymphoma requiring systemic therapy.
    • Evaluate the preliminary safety profiles and response outcomes of investigational agents and treatment strategies undergoing evaluation in NHL and CLL, and counsel appropriately selected patients about the potential for enrollment in clinical trials.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


    This educational activity for 3 contact hours is provided by Research To Practice during the period of March 2013 through March 2014.


    This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.

    To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located at ResearchToPractice.com/ONUNHL113/CNE. A statement of CNE credit will be issued only upon completion of the Post-test, with a score of 70% or better, and the Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Amy Goodrich, CRNP-AC

    Nurse Practitioner
    Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland

    No real or apparent conflicts of interest to disclose.

    Mitchell R Smith, MD, PhD
    Director of Lymphoid Malignancies Program at Taussig Cancer Institute
    Cleveland Clinic
    Cleveland, Ohio

    Advisory Committee: Cephalon Inc; Speakers Bureau: Allos Therapeutics, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    Steven M Horwitz, MD

    Assistant Attending
    Lymphoma Service, Division of Hematologic Oncology
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Advisory Committee: Allos Therapeutics, Celgene Corporation; Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Seattle Genetics, Spectrum Pharmaceuticals Inc; Paid Research: Allos Therapeutics, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc.

    Mollie Moran, MSN, CNP, AOCNP
    The James Cancer Hospital at The Ohio State University
    Columbus, Ohio

    No real or apparent conflicts of interest to disclose.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation and Genentech BioOncology/Biogen Idec.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Oncology Nursing Update: Non-Hodgkin Lymphoma Edition, Issue 1, 2013
Released March 2013

Featuring interviews with Ms Amy Goodrich, Drs Mitchell R Smith and Steven M Horwitz and Ms Mollie Moran. (Audio Content)

Read print: